Advertisement

Topics

FDA Accepts and Grants Priority Review of Novartis’ Brolucizumab for Patients with Wet Age-Related Macular Degeneration

12:02 EDT 16 Apr 2019 | Speciality Pharma Journal

Basel, April 15, 2019 – Novartis announced that the US Food and Drug Administration (FDA) accepted the company’s Biologics License Application (BLA) for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration (AMD), also known as neovascular AMD, or nAMD. Seeking to make brolucizumab available as quickly as possible, Novartis used a priority review voucher to …

Original Article: FDA Accepts and Grants Priority Review of Novartis’ Brolucizumab for Patients with Wet Age-Related Macular Degeneration

NEXT ARTICLE

More From BioPortfolio on "FDA Accepts and Grants Priority Review of Novartis’ Brolucizumab for Patients with Wet Age-Related Macular Degeneration"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...